Funded Biotechnology Startups in Barcelona
Disclosed biotech funding in Barcelona is led by Ona Therapeutics, which raised $87M on 2026-06-04; that single round sits far above the next-largest discl…
Disclosed biotech funding in Barcelona is led by Ona Therapeutics, which raised $87M on 2026-06-04; that single round sits far above the next-largest disclosed amounts in the list (Splice Bio’s $135M on 2025-06-11 and Atrys Health’s $76M on 2022-06-15) and generally contrasts with multiple rounds in the low single-digit millions (e.g., Molecular Gate $530K on 2026-03-02; Devicare $1M on 2026-02-09). Stage labels are also uneven: “Series Unknown” appears frequently across these 35 entries (10 “Series Unknown” rows, plus 1 explicitly “undisclosed”), while named stages range from Pre-Seed (Kamleon, $1M on 2023-11-07) to Post-IPO Equity (Atrys Health, $76M on 2022-06-15).
Temporal clustering is visible in 2025, where several rounds concentrate in May–July 2025 (e.g., Seqera $26M and INBRAIN Neuroelectronics $5M on 2025-05-06; Minoryx Therapeutics $31M and Oryzon Genomics $16M on 2025-07-10; Splice Bio $135M on 2025-06-11). The date window spans 2021-09-16 (Aelix Therapeutics, $2M) through 2026-06-08 (Gate2Brain, $8M), with all companies listed as being based in Barcelona, Catalonia, Spain.
Most recent rounds
35 shownRelated listings
Frequently asked
What is the largest disclosed round in this Barcelona biotech list, and how does it compare to the rest?
Splice Bio’s $135M (2025-06-11) is the top disclosed amount in the 35 rows, materially above other large disclosed rounds such as Ona Therapeutics $87M (2026-06-04) and Atrys Health $76M (2022-06-15). Outside that upper tier, several entries cluster much lower—for example, Molecular Gate at $530K (2026-03-02) and Bioinspired Materials at $840K (2025-05-20).
Is there a notable concentration of rounds in a specific time window?
Yes—May to July 2025 shows multiple closings: Seqera raised $26M on 2025-05-06, INBRAIN Neuroelectronics raised $5M on 2025-05-06, Splice Bio raised $135M on 2025-06-11, and Minoryx Therapeutics ($31M) plus Oryzon Genomics ($16M) closed on 2025-07-10. There are also multiple late-Q1/Q1 2026 events (e.g., Gate2Brain $8M on 2026-06-08 and Molecular Gate $530K on 2026-03-02).
How dominant is “Series Unknown,” and does it create blind spots in stage interpretation?
“Series Unknown” appears in 10 of the 35 rows, and there is 1 additional row explicitly marked “undisclosed” (IMIDomics on 2024-03-04). Named stages still recur—Seed appears in several entries such as Molecular Gate ($530K, 2026-03-02) and Bioinspired Materials ($840K, 2025-05-20)—but the high “Unknown” share reduces confidence when comparing across stage categories.
Which stages show up repeatedly among named labels, and what does that suggest about the funding mix?
Among named stages (excluding “Series Unknown” and “undisclosed”), Seed is prominent in multiple entries—e.g., Molecular Gate $530K (2026-03-02), Bioinspired Materials $840K (2025-05-20), and Connecta Therapeutics $3M (2024-02-12). Series B also appears more than once, including Ona Therapeutics $87M (2026-06-04) and Splice Bio $135M (2025-06-11), indicating larger disclosed rounds aren’t confined to early-stage labels.
Are there outliers besides the largest round that stand out for unusually small disclosed amounts or non-standard classifications?
Rethink Medical is an extreme low disclosed outlier at $10K (2023-10-12) compared with nearby seed/series amounts like Connecta Therapeutics $3M (2024-02-12) and ADmit Therapeutics $6M (2023-10-05). There are also non-standard classifications: Atrys Health is listed as “Post-IPO Equity” ($76M on 2022-06-15), and Peptomyc is labeled “Venture - Series Unknown” ($3M on 2022-01-18), which can affect how rounds should be compared.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.